Analyst firms · Raymond James · ABT

Raymond James ABT price target and rating history

Abbott Laboratories (ABT) · Health Care

Raymond James rates Abbott Laboratories (ABT) Outperform with a $123 price target, as of its latest action on Apr 20, 2023. It has published 5 rating actions on ABT since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a ABT price target in the last 12 months, the median target is $121.

Current rating
Outperform
Price target
$123
Median target, all firms
$121
Actions on ABT
5

Raymond James price target on ABT

$150$137$12320222023202420252026
Raymond James price target on ABT, each point a stated target, July 2021 to April 2023.

Every Raymond James rating on ABT

How other firms rate ABT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchHoldOct 27, 2026
BarclaysOverweight$120Oct 7, 2026
Rothschild & Co RedburnBuy$127Oct 2, 2026
Wolfe ResearchOutperform$130Aug 13, 2026
Robert W. BairdOutperform$121Jul 1, 2026
DaiwaNeutral$92Apr 22, 2026

Questions about Raymond James and ABT

What is Raymond James's price target for ABT?
Raymond James's latest stated price target for Abbott Laboratories (ABT) is $123, from its action on Apr 20, 2023.
What is Raymond James's rating on ABT?
Raymond James rates ABT Outperform, a bullish rating, as of Apr 20, 2023.
When did Raymond James last change its view on ABT?
On Apr 20, 2023, Raymond James raises its price target to $123 from $116, keeps Outperform.
How does Raymond James's ABT target compare with other analysts?
Across 5 firms with a ABT price target in the last 12 months, the median target is $121.

More ABT rating histories

All Raymond James ratingsABT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.